TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03282617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD137L-DC-EBV-VAX
Description: Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD137L-DC-EBV-VAX
Description: Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
Study: NCT04529096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT00394992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin+capecitabine
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+capecitabine+bevacizumab
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
Study: NCT03716804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet Nitrofurantoin
Description: Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime
Description: Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
Study: NCT03402126

Intervention type: OTHER
Intervention: TPD RAMWare
Description: TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
Study: NCT03654365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk ordering and bulk messaging
Description: Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine alerting
Description: Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine alerting
Description: Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
Study: NCT02093650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: black cohosh extract
Description: Black cohosh extract 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soy bean oil
Study: NCT02275182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
Study: NCT04012008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Description: * Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: * Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case
Study: NCT00457418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Study: NCT02261974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment Viveve
Description: Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment Viveve
Description: Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
Study: NCT02108366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
Study: NCT03250507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% bupivacaine for TAP block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine for TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Exparel for TAP block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Exparel for TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
Study: NCT04179123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised PAP interfaces
Description: Customised PAP interfaces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised PAP interfaces
Description: Customised PAP interfaces
Study: NCT01366365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylnaltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04811911

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Patients will receive 8 sessions of NB-UVB per month for 3 successive months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Study: NCT04295109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the drug of intravenous patient-controlled analgesia
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the drug of intravenous patient-controlled analgesia
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the drug of intravenous patient-controlled analgesia
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Study: NCT01817335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Participate in psycho-educational program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in psycho-educational program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication skills training
Description: Participate in psycho-educational program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03225066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid - Sculptra
Description: Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
Study: NCT04200781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granules of Shengdi Dahuang Decoction
Description: Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules has the same appearence, weight, shape and color as the experimental drug.
Study: NCT01579292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based physical activity with intervention
Description: This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer Only
Description: This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
Study: NCT05194280

Intervention type: PROCEDURE
Intervention: Robotic surgery
Description: Robotic-assisted donornephrectomy
Study: NCT03455088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: fluoxetine
Description: Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: fluoxetine
Description: Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
Study: NCT03870880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg
Description: Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 100 mg
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study: NCT02220764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teeth abutment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant abutments
Study: NCT01499264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MySkin patch
Description: Hydrogel and polyurethane film

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Dressing
Description: Gauze and Patch
Study: NCT04335890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with IKKb matured Dendritic Cells
Description: IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
Study: NCT02386319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04998565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Reverse pressure applied to the areola

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Reverse pressure applied to the areola

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Reverse pressure applied to the areola

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Acupuncture
Description: Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation over bil breasts
Study: NCT01069198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole, Iron, Zinc and Vitamin A
Description: single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged \<5 and \>=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01856725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic measurements for CRT device programming

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT device implant with MultiPoint Pacing
Study: NCT01003249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study: NCT01856725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT device implant with MultiPoint Pacing
Study: NCT03028207

Intervention type: PROCEDURE
Intervention: Medical tests
Description: During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.

Intervention type: PROCEDURE
Intervention: Medical tests
Description: During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.

Intervention type: OTHER
Intervention: Questionnaire
Description: During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.

Intervention type: OTHER
Intervention: Questionnaire
Description: During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
Study: NCT01971528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic muscle stimulator
Description: Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength training
Description: Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
Study: NCT02714218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV
Description: Followed by Nivolumab monotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg IV
Description: Followed by Nivolumab monotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg IV
Description: Followed by Nivolumab monotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab 6 mg/kg IV
Description: A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to \~ 480mg.
Study: NCT02881853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01275846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Guide using AHA heart failure protocols and content
Description: Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
Study: NCT04409145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT30
Description: VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.
Study: NCT01942577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NoSting
Description: Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
Study: NCT02254317

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 mg placebo
Description: Not containing GSE (Placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg GSE
Description: 300 mg GSE

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 mg GSE
Description: Containing 600 mg of GSE

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 900 mg GSE
Description: Containing 900 mg of GSE
Study: NCT01381211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE-DEB
Description: Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90Y-RE
Description: Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
Study: NCT00420420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0249
Description: MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
Study: NCT01422200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2011-2012 seasonal flu vaccine Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2011-2012 seasonal flu vaccine Intramuscular
Study: NCT03977896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 11C-MET PET/MRI
Description: Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL).
Study: NCT00918866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
Study: NCT03236467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Exercise Training
Description: Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
Study: NCT02066844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celestone
Description: 2cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone
Description: 2cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5cc
Study: NCT01707173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education
Description: Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Education
Description: Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices